RESUMO
Preconception care refers to a set of interventions that identify and address biomedical, behavioral, and social risks to a woman's health that may negatively impact a future pregnancy. A great need for preconception care currently exists in the United States, and women's attitudes about discussions with health care providers about healthy and safe pregnancies are positive. Clinical pharmacists are well positioned to work with other health care and public health professionals to ensure that all women of childbearing potential have access to preconception care. As part of the collaborative health care team, clinical pharmacists can directly provide services or support and referrals to other members of the health care team or to community resources through clinical-community linkages. Specifically, clinical pharmacists can provide education, counseling, and/or services to women to address family planning, medication and disease state management, immunizations, screenings, health promotion, and substance use. Clinical pharmacists can also impact preconception care through drug information services, advocacy, and research. Preconception care services can be incorporated into daily pharmacy practice, and there are potential means for reimbursement. Multiple roles exist for clinical pharmacists to fulfill unmet needs in preconception care.
Assuntos
Serviços Comunitários de Farmácia , Acessibilidade aos Serviços de Saúde , Farmacêuticos , Cuidado Pré-Concepcional , Papel Profissional , Adolescente , Adulto , Algoritmos , Serviços Comunitários de Farmácia/economia , Serviços Comunitários de Farmácia/tendências , Anticoncepção/efeitos adversos , Anticoncepção/economia , Anticoncepção/métodos , Anticoncepção/tendências , Árvores de Decisões , Serviços de Informação sobre Medicamentos/economia , Serviços de Informação sobre Medicamentos/tendências , Serviços de Planejamento Familiar/economia , Serviços de Planejamento Familiar/educação , Serviços de Planejamento Familiar/tendências , Feminino , Custos de Cuidados de Saúde , Promoção da Saúde/economia , Promoção da Saúde/tendências , Acessibilidade aos Serviços de Saúde/economia , Acessibilidade aos Serviços de Saúde/tendências , Humanos , Área Carente de Assistência Médica , Educação de Pacientes como Assunto , Farmacêuticos/economia , Cuidado Pré-Concepcional/economia , Cuidado Pré-Concepcional/tendências , Estados Unidos , Recursos Humanos , Adulto JovemRESUMO
BACKGROUND: Medications are an effective intervention for managing and preventing health problems but their benefit can be undermined by non-adherence or adverse drug events (ADEs). Since these issues may be interconnected, efforts to improve non-adherence should also include reduction of ADEs. We have developed the ISTOP-ADE system (Information Systems-enabled Outreach for Preventing Adverse Drug Events), which enables timely monitoring and managing of ADEs. The objectives of this study are to determine whether the ISTOP-ADE system, compared to routine care, will reduce: a) the probability of discontinuing the use of prognosis-altering medications; b) the probability of a patient experiencing a severe ADE; c) the proportion of patients experiencing ADEs, preventable ADEs and ameliorable ADEs; and d) health services utilization. METHODS/DESIGN: We will randomly assign 2,200 adult ambulatory patients in the province of Québec who have been prescribed an incident medication for the management or prevention of a chronic health condition, to routine care or the ISTOP-ADE system. The ISTOP-ADE system consists of an interactive voice response system (IVRS) paired with pharmacist support. The IVRS will call patients at 3 and 17 days post-prescription to determine if they are experiencing any problems and connect them with a pharmacist when required or desired by the patient. We will evaluate medication persistence at 180 days and health-care utilization using provincial administrative data. Two blinded physicians will ascertain ADE status through a case review. DISCUSSION: We expect the ISTOP-ADE intervention to be feasible and to improve the quality of patient care through improved medication adherence, reduced ADE duration and reduced number of ADEs resulting in an emergency department or inpatient encounter. This in turn could lower health-care utilization, saving costs and lowering the burden on emergency departments and family practices. The success of ISTOP-ADE would present opportunities to implement this intervention through health systems, health insurance agents and commercial pharmacies. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02059044. Date registered: 10 January 2014.
Assuntos
Assistência Ambulatorial , Serviços Comunitários de Farmácia , Serviços de Informação sobre Medicamentos , Quimioterapia Assistida por Computador/métodos , Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos/prevenção & controle , Adesão à Medicação , Projetos de Pesquisa , Assistência Ambulatorial/economia , Protocolos Clínicos , Serviços Comunitários de Farmácia/economia , Análise Custo-Benefício , Serviços de Informação sobre Medicamentos/economia , Prescrições de Medicamentos , Quimioterapia Assistida por Computador/economia , Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos/economia , Custos de Cuidados de Saúde , Recursos em Saúde/economia , Recursos em Saúde/estatística & dados numéricos , Pesquisa sobre Serviços de Saúde , Humanos , Segurança do Paciente , Quebeque , Telefone , Fatores de Tempo , Resultado do TratamentoRESUMO
OBJECTIVE: The number of lawsuits accusing pharmaceutical companies of off-label marketing has risen in recent years. The impact of such lawsuits on drug prescribing and spending has not been examined. We evaluated a nationwide sample to determine whether the $430 million gabapentin off-label marketing lawsuit and accompanying media coverage affected gabapentin market share, substitution of other scientifically substantiated and unsubstantiated anticonvulsants, and anticonvulsant spending of Medicare/Medicaid patients diagnosed with bipolar disorder. METHOD: Using a national 5% sample of Medicare recipients linked to Medicaid claims, we used an interrupted times series design to evaluate the impact of the lawsuit on monthly market share, utilization, and spending from January 1, 2001, to December 31, 2005. RESULTS: The start of the lawsuit was associated with a 28% relative reduction in gabapentin market share (from â¼ 21% to â¼ 15%) and a reduction in the rate of prescribing from 108 prescriptions per 1,000 patients per month before the start of the lawsuit to 90 by the end of follow-up (P < .001). We also observed increases in market share for 3 other anticonvulsants. Total anticonvulsant use and spending per 1,000 patients increased by 13% and 74%, respectively, after the intervention. The increase in anticonvulsant spending was equivalent to $7,554 per 1,000 patients per year higher than expected compared with the baseline trend (P = .01). CONCLUSIONS: We conclude that the lawsuit resulted in a reduction in gabapentin market share, increased market share for other anticonvulsants, and substantially increased total anticonvulsant spending to approximately half of the settlement amount, not counting substitutions of newer drugs for other illnesses affected by the lawsuit. These findings support the need for further study of the effects of current lawsuits regarding off-label drug marketing.
Assuntos
Aminas/uso terapêutico , Anticonvulsivantes/uso terapêutico , Transtorno Bipolar/tratamento farmacológico , Ácidos Cicloexanocarboxílicos/uso terapêutico , Indústria Farmacêutica/legislação & jurisprudência , Marketing/legislação & jurisprudência , Uso Off-Label/legislação & jurisprudência , Padrões de Prática Médica/legislação & jurisprudência , Ácido gama-Aminobutírico/uso terapêutico , Aminas/efeitos adversos , Aminas/economia , Anticonvulsivantes/efeitos adversos , Anticonvulsivantes/economia , Transtorno Bipolar/psicologia , Compensação e Reparação/legislação & jurisprudência , Ácidos Cicloexanocarboxílicos/efeitos adversos , Ácidos Cicloexanocarboxílicos/economia , Aprovação de Drogas/economia , Aprovação de Drogas/legislação & jurisprudência , Custos de Medicamentos/legislação & jurisprudência , Indústria Farmacêutica/economia , Serviços de Informação sobre Medicamentos/economia , Substituição de Medicamentos/economia , Substituição de Medicamentos/estatística & dados numéricos , Uso de Medicamentos/economia , Uso de Medicamentos/legislação & jurisprudência , Uso de Medicamentos/estatística & dados numéricos , Gabapentina , Humanos , Seguro de Serviços Farmacêuticos/economia , Seguro de Serviços Farmacêuticos/legislação & jurisprudência , Seguro de Serviços Farmacêuticos/estatística & dados numéricos , Marketing/economia , Meios de Comunicação de Massa/estatística & dados numéricos , Medicaid/economia , Medicaid/legislação & jurisprudência , Medicaid/estatística & dados numéricos , Medicare/economia , Medicare/legislação & jurisprudência , Medicare/estatística & dados numéricos , Uso Off-Label/economia , Padrões de Prática Médica/economia , Padrões de Prática Médica/estatística & dados numéricos , Resultado do Tratamento , Estados Unidos , Ácido gama-Aminobutírico/efeitos adversos , Ácido gama-Aminobutírico/economiaRESUMO
Funding for Teratology Information Services has been an ongoing struggle over the 25 years of its existence. Traditional and novel funding mechanisms have been explored with varying success. The importance of providing teratology risk assessment and counseling to all women of reproductive age is now an established health care objective. Sufficient and stable funding for these services is essential.
Assuntos
Aconselhamento/economia , Serviços de Informação sobre Medicamentos/economia , Reprodução , Teratologia/economia , Aconselhamento/educação , Serviços de Informação sobre Medicamentos/organização & administração , Feminino , Humanos , Exposição Materna/efeitos adversos , Medição de Risco , Teratogênicos/toxicidade , Teratologia/educação , Teratologia/organização & administraçãoRESUMO
The growing importance of the Internet as an information and purchasing channel is drawing widespread attention from marketing decision makers. Nevertheless, the relevance of the Internet to the so-called self-medication market in Germany has been paid barely enough attention. Our study aims to contribute insights concerning the penetration of the Internet in this market, as well as to give an overview of the critical determinants of Internet use for non-prescription drug information seeking, such as the accessibility of professional information, trust in health professionals' opinion and the ability to search online, as well as the perceived usefulness and credibility of online non-prescription drug information. Furthermore, we demonstrate that the preferred use of the Internet as a non-prescription drug information source positively influences the choice of unconventional purchase channels for non-prescription drugs and negatively affects the use of stationary pharmacies.
Assuntos
Publicidade/métodos , Participação da Comunidade/psicologia , Conhecimentos, Atitudes e Prática em Saúde , Armazenamento e Recuperação da Informação/métodos , Internet/estatística & dados numéricos , Medicamentos sem Prescrição , Assistência Farmacêutica , Adolescente , Adulto , Idoso , Comércio/métodos , Comércio/estatística & dados numéricos , Participação da Comunidade/estatística & dados numéricos , Serviços de Informação sobre Medicamentos/economia , Serviços de Informação sobre Medicamentos/estatística & dados numéricos , Feminino , Alemanha , Humanos , Entrevistas como Assunto , Análise dos Mínimos Quadrados , Masculino , Pessoa de Meia-Idade , Medicamentos sem Prescrição/economia , Medicamentos sem Prescrição/normas , Medicamentos sem Prescrição/provisão & distribuição , Assistência Farmacêutica/economia , Assistência Farmacêutica/normas , Assistência Farmacêutica/estatística & dados numéricos , Marketing Social , Inquéritos e Questionários , ConfiançaRESUMO
BACKGROUND: Medication errors are common in primary care and are associated with considerable risk of patient harm. We tested whether a pharmacist-led, information technology-based intervention was more effective than simple feedback in reducing the number of patients at risk of measures related to hazardous prescribing and inadequate blood-test monitoring of medicines 6 months after the intervention. METHODS: In this pragmatic, cluster randomised trial general practices in the UK were stratified by research site and list size, and randomly assigned by a web-based randomisation service in block sizes of two or four to one of two groups. The practices were allocated to either computer-generated simple feedback for at-risk patients (control) or a pharmacist-led information technology intervention (PINCER), composed of feedback, educational outreach, and dedicated support. The allocation was masked to researchers and statisticians involved in processing and analysing the data. The allocation was not masked to general practices, pharmacists, patients, or researchers who visited practices to extract data. [corrected]. Primary outcomes were the proportions of patients at 6 months after the intervention who had had any of three clinically important errors: non-selective non-steroidal anti-inflammatory drugs (NSAIDs) prescribed to those with a history of peptic ulcer without co-prescription of a proton-pump inhibitor; ß blockers prescribed to those with a history of asthma; long-term prescription of angiotensin converting enzyme (ACE) inhibitor or loop diuretics to those 75 years or older without assessment of urea and electrolytes in the preceding 15 months. The cost per error avoided was estimated by incremental cost-effectiveness analysis. This study is registered with Controlled-Trials.com, number ISRCTN21785299. FINDINGS: 72 general practices with a combined list size of 480,942 patients were randomised. At 6 months' follow-up, patients in the PINCER group were significantly less likely to have been prescribed a non-selective NSAID if they had a history of peptic ulcer without gastroprotection (OR 0·58, 95% CI 0·38-0·89); a ß blocker if they had asthma (0·73, 0·58-0·91); or an ACE inhibitor or loop diuretic without appropriate monitoring (0·51, 0·34-0·78). PINCER has a 95% probability of being cost effective if the decision-maker's ceiling willingness to pay reaches £75 per error avoided at 6 months. INTERPRETATION: The PINCER intervention is an effective method for reducing a range of medication errors in general practices with computerised clinical records. FUNDING: Patient Safety Research Portfolio, Department of Health, England.
Assuntos
Serviços Comunitários de Farmácia/economia , Serviços de Informação sobre Medicamentos/economia , Erros de Medicação/prevenção & controle , Farmacêuticos/economia , Antagonistas Adrenérgicos beta , Amiodarona , Inibidores da Enzima Conversora de Angiotensina , Antiarrítmicos , Anti-Inflamatórios não Esteroides , Antimaníacos , Asma/epidemiologia , Serviços Comunitários de Farmácia/organização & administração , Anticoncepcionais Orais Hormonais , Contraindicações , Análise Custo-Benefício , Serviços de Informação sobre Medicamentos/organização & administração , Monitoramento de Medicamentos , Eletrólitos/análise , Inglaterra/epidemiologia , Medicina de Família e Comunidade , Retroalimentação Psicológica , Humanos , Imunossupressores , Compostos de Lítio , Erros de Medicação/economia , Metotrexato , Úlcera Péptica/tratamento farmacológico , Úlcera Péptica/epidemiologia , Inibidores da Bomba de Prótons/uso terapêutico , Análise de Regressão , Inibidores de Simportadores de Cloreto de Sódio e Potássio , Ureia/análiseRESUMO
This study investigated the influence of drug-company funding on websites about attention-deficit hyperactivity disorder (ADHD). Websites in the top 60 for either Google or Yahoo!Xtra with information about causation and treatment were analysed. Likert scales, based on those used in previous similar studies, were developed to rate aetiological explanations and recommended treatment approaches, on a dimension from psycho-social to biological. Overall, the quality of information on websites was poor with a strong bias towards bio-genetic aetiological explanations of ADHD. Twenty-one of the 57 websites (37%) were funded by drug companies. The drug-company funded (DCF) websites were significantly more likely than non-DCF websites to recommend medication rather than psycho-social treatments. The selective lack of consideration of psycho-social treatments by DCF websites is discussed in relation to the relevant research literature, including the evidence in favour of a multimodal approach. The findings, which are consistent with previous similar studies in relation to websites about adult mental health problems, confirm that the pharmaceutical industry is seeking to influence public opinion via the internet.
Assuntos
Transtorno do Deficit de Atenção com Hiperatividade/tratamento farmacológico , Indústria Farmacêutica/economia , Serviços de Informação sobre Medicamentos/economia , Internet/economia , Marketing/instrumentação , Educação de Pacientes como Assunto/economia , Transtorno do Deficit de Atenção com Hiperatividade/economia , HumanosRESUMO
Objetivos. Describir el importe mensual de medicamentos por habitante estandarizado del departamento de salud Valencia-Doctor Peset y correlacionarlo con la informatización de la prescripción en consulta mediante análisis de series temporales. Otros objetivos fueron identificar causas que puedan explicar las variaciones observadas en el indicador, así como evaluar los costes asociados a estas modificaciones. Material y métodos.Estudio observacional longitudinal retrospectivo que analizó las variables: a) importe mensual de medicamentos por habitante estandarizado, y b) dosis por 1.000 habitantes y día (DHD) de medicamentos para prevenir el riesgo cardiovascular prescritos por los médicos de familia del departamento Valencia-Doctor Peset entre enero de 2001 y agosto de 2009. Las series temporales se ajustaron mediante modelos Promedio Móvil Integrado de Autoregresión (ARIMA). El efecto de la informatización de la prescripción se valoró cualitativa y cuantitativamente mediante un análisis de intervención en series temporales. Resultados. El análisis de intervención realizado con modelos ARIMA para el importe mensual por habitante estandarizado y la DHD de medicamentos para prevenir el riesgo cardiovascular reveló incrementos del 4,9 y el 8,5% en agosto de 2007 respectivamente. Ambos aumentos coincidieron con la implantación de la prescripción informatizada en los centros de salud del departamento. El estudio farmacoeconómico asociado estimó que el coste de los medicamentos en los 24 meses transcurridos desde agosto de 2007 se incrementó en 11.365.409 euros. Conclusiones. La informatización de la prescripción en la consulta de los médicos de familia puede correlacionarse con incrementos del importe mensual por habitante estandarizado y de las DHD de medicamentos para prevenir el riesgo cardiovascular del 4,9 y el 8,5% respectivamente(AU)
Objectives. To describe the monthly costs of drugs per standardized patient in the Doctor Peset health department in Valencia, Spain and to correlate them with the computerization of prescription in primary care clinics using time series analysis. Other objectives were to identify internal causes that could explain the variations observed, and to evaluate the drug costs associated with these variations. Material and methods. Observational and retrospective study to analyse the variables: a) monthly costs of drugs by standardized patient and b) number of defined daily doses (DDD) per 1000 inhabitants and per day of drugs used to prevent cardiovascular risk prescribed by the Primary Care doctors of the Doctor Peset health department in Valencia, between January 2001 and August 2009. Time series were adjusted using ARIMA models. The impact of computerization was assessed using an intervention analysis on time series. Results. ARIMA models for the monthly costs of drugs by standardized patient shows that this indicator was increased by 4.9% in August 2007. The modelling of daily DDD per 1000 inhabitants showed an increase of 8.5% on the same date. Both increases occurred together with the introduction of the computerized prescription in Primary Care clinics. The pharmacoeconomic study estimated that drug costs associated with the trend changes increased by 11,365,409 euros within the period September 2007 to August 2009. Conclusions. The computerization of prescription in Primary Care clinics can be correlated with an increase in the monthly costs of drugs per standardized patient and with the number of daily DDD per 1000 inhabitants of drugs to reduce the cardiovascular risk by 4.5% and 8.5%, respectively(AU)
Assuntos
Humanos , Masculino , Feminino , Atenção Primária à Saúde/métodos , Controle de Medicamentos e Entorpecentes/economia , Serviços de Informação sobre Medicamentos/economia , Custos de Medicamentos/estatística & dados numéricos , Custos de Medicamentos/normas , Custos de Medicamentos/tendências , Farmacoepidemiologia , Prescrições de Medicamentos/economia , Legislação de Medicamentos/economia , Atenção Primária à Saúde/economia , Atenção Primária à Saúde/tendências , Atenção Primária à Saúde , Custos e Análise de Custo/economia , Estudos Retrospectivos , Estudos Longitudinais , 28599RESUMO
Even though from preclinical testing to drug risk labeling, the situation with drugs in pregnancy has improved substantially since the thalidomide scandal, there is still an increasing need to provide healthcare professionals and patients with updated individualized risk information for clinical decision making. For the majority of drugs, clinical experience is still insufficient with respect to their safety in pregnancy. There is often uncertainty in how to interpret the available scientific data. Based on 20 years of experience with Teratology Information Services (TIS) cooperating in the European Network of Teratology Information Services (ENTIS) methods of risk interpretation, follow-up of exposed pregnancies through the consultation process and their evaluation is discussed. Vitamin K antagonists, isotretinoin and angiotensin (AT) II-receptor-antagonists are presented as examples of misinterpretation of drug risks and subjects of research based on observational clinical data recorded in TIS. As many TIS are poorly funded, advocacy is necessary by establishing contacts with decision makers in health politics and administration, informing them of the high return in terms of health outcomes and cost savings provided by TIS as reference institutions in clinical teratology.
Assuntos
Anormalidades Induzidas por Medicamentos/prevenção & controle , Serviços de Informação sobre Medicamentos , Gravidez , Teratologia , 4-Hidroxicumarinas/efeitos adversos , Antagonistas de Receptores de Angiotensina/efeitos adversos , Anticoagulantes/efeitos adversos , Serviços de Informação sobre Medicamentos/economia , Feminino , Humanos , Complicações na Gravidez , Retinoides/efeitos adversos , Medição de Risco , Vitamina K/antagonistas & inibidoresRESUMO
Pharmacists working in the intensive care unit (ICU) in Saiseikai Yokohamashi Tobu Hospital are mainly responsible for managing the stock of drugs, providing drug information to other medical staff, educating them for rational drug therapy, and providing pharmaceutical care to the patients. In order to evaluate the contribution to the rational drug therapy, we investigated the acceptance rate of the drug information that the pharmacists in the ICU provided to the physicians from February to May in 2009. The number of cases in which drug information was provided by the pharmacists to the physicians during the period was 288. It was suggested that more than half of the information could optimize the drug dosage regimens and correct the inadequate prescriptions. Furthermore, 98.9% of the information provided by pharmacists was accepted by physicians. We questioned 5 intensivists to evaluate the information with a 5 point scale (maximum score was 4, minimum score was 0) and then the average of score was 3.3. In addition, their evaluation of the information about optimizing the drug dosage regimens marked the highest point (over 3.5). Meanwhile, providing drug information which led the physicians to correct the inadequate prescriptions contributed to reduce the cost of the drug therapy by 900000 yen during the period. As a result, it was suggested that the intensivists highly appreciated the information offered by the pharmacists and the information contributed to enhance high-quality drug therapy. Additionally, the economic impact was identified through the cost reduction in drug therapy.
Assuntos
Redução de Custos/estatística & dados numéricos , Custos de Medicamentos/estatística & dados numéricos , Serviços de Informação sobre Medicamentos/economia , Serviços de Informação sobre Medicamentos/estatística & dados numéricos , Tratamento Farmacológico/economia , Uso de Medicamentos/economia , Unidades de Terapia Intensiva/economia , Unidades de Terapia Intensiva/estatística & dados numéricos , Farmacêuticos/estatística & dados numéricos , Humanos , Japão/epidemiologiaAssuntos
Serviços de Informação sobre Medicamentos/organização & administração , Programas Nacionais de Saúde/organização & administração , Assistência Farmacêutica/organização & administração , Serviços Contratados/economia , Serviços Contratados/organização & administração , Serviços Contratados/tendências , Controle de Custos/métodos , Aprovação de Drogas/economia , Aprovação de Drogas/métodos , Serviços de Informação sobre Medicamentos/economia , Serviços de Informação sobre Medicamentos/tendências , Revisão de Uso de Medicamentos , Medicina Baseada em Evidências/economia , Medicina Baseada em Evidências/tendências , Humanos , Sistemas de Medicação no Hospital/organização & administração , Programas Nacionais de Saúde/economia , Programas Nacionais de Saúde/tendências , Assistência Farmacêutica/economia , Assistência Farmacêutica/tendências , EscóciaRESUMO
Fundamento: MIURA (Modelo Integrado para el Uso Racional de Antimicrobianos) es un proyecto que se inicio en enero de 2004 y finalizó en diciembre de 2006. Mediante intervenciones trimestrales y formativas dirigidas a médicos, farmacéuticos y pacientes, pretendió mejorar el uso de antibióticos en un área de salud. El objetivo ha sido analizar la evolución en el consumo de antibióticos y evaluar la repercusión de la implantación de este proyecto en un área de salud. Método: Se realizó un estudio comparativo sobre la evolución de la dispensación de antibióticos con receta durante los periodos 2000-03 (pre-MIURA), 2004-06 (MIURA) y 2007-08 (post-MIURA) en el Departamento de Salud 11 de la Comunidad Valenciana. La información se obtuvo a través de la aplicación informática GAIA (Generalitat Valenciana) que recoge información sobre los medicamentos facturados por las oficinas de farmacia a través de las recetas oficiales. Como unidad técnica de medida se empleó la DHD (Dosis diaria definida/1.000 Habitantes/Día). Resultados: Durante el periodo de implantación del proyecto (2004 a 2006), se detectó un descenso global de 4,02 DHD en el consumo de antibióticos, lo que representa una reducción global y significativa del 15% (p<0.05). Durante el periodo del MIURA se observó una disminución estadísticamente significativa en los valores de DHD para los grupos terapéuticos de macrólidos (especialmente claritromicina) y de cefalosporinas; también se detectó una disminución, aunque no significativa, para el grupo de las quinolonas, mientras que los grupos correspondientes a las penicilinas y a otros antibióticos no presentaron cambios. En el periodo post-MIURA se detectó un nuevo incremento en la dispensación de los antibióticos. Conclusiones: El programa MIURA ha influido positivamente en la disminución de la prescripción de antibióticos en nuestra área de salud, como demuestra el descenso en DHD durante el periodo de intervenciones(AU)
Background: MIURA (Integrated Model for the Rational Use of Antimicrobials) is a project that began in January 2004 and ended in December 2006. Through quarterly and training interventions intented for physicians, pharmacists and patients, pretends to improve antibiotic use in a health area. The goal was to analyze the evolution of antibiotic consumption and assess the impact of implementing this project in a health area. Method: A comparative study on the evolution of antibiotic dispensed during the periods 2000-03 (pre-MIURA), 2004-06 (MIURA) and 2007-08 (post-MIURA) in the Department of Health 11 of Valencia was conduced. Antibiotics information was obtained through the GAIA application (Generalitat Valenciana) that collects information about the drugs billed by the pharmacy through the official prescriptions. Technical unit of measurement was used DHD (daily dose defined/1.000 inhabitants / day). Results: During the implementation of the project (2004-2006), antibiotic consumption was reduced in 4.02 DHD. It represents a statistically significant overall reduction from 15% (p= <0.05). Since interventions started, a statistically significant decrease in DHD values was observed for macrolides (especially clarithromycin) and cephalosporines. It also exist an average decrease, not significant, for the group of quinolones, whereas penicillins and other antibiotics havent showed variability in the consumption data. In the post-MIURA period was detected a further increase in the dispensing of antibiotics. Conclusions: MIURA program has positively influenced on decreasing antibiotic prescription in our health area, as shows the decrease in DHD during the interventions(AU)
Assuntos
Humanos , Masculino , Feminino , Antibacterianos/economia , Antibacterianos/provisão & distribuição , Serviços de Informação sobre Medicamentos/economia , Serviços de Informação sobre Medicamentos/organização & administração , Serviços de Informação sobre Medicamentos/provisão & distribuição , Avaliação de Medicamentos , Macrolídeos/economia , Macrolídeos/provisão & distribuiçãoAssuntos
Serviços de Informação sobre Medicamentos/estatística & dados numéricos , Farmacêuticos/estatística & dados numéricos , Encaminhamento e Consulta/estatística & dados numéricos , Serviços de Informação sobre Medicamentos/economia , Humanos , Educação de Pacientes como Assunto/economia , Encaminhamento e Consulta/economia , Encaminhamento e Consulta/tendências , WyomingRESUMO
BACKGROUND: Medication errors are an important cause of morbidity and mortality in primary care. The aims of this study are to determine the effectiveness, cost effectiveness and acceptability of a pharmacist-led information-technology-based complex intervention compared with simple feedback in reducing proportions of patients at risk from potentially hazardous prescribing and medicines management in general (family) practice. METHODS: RESEARCH SUBJECT GROUP: "At-risk" patients registered with computerised general practices in two geographical regions in England. DESIGN: Parallel group pragmatic cluster randomised trial. INTERVENTIONS: Practices will be randomised to either: (i) Computer-generated feedback; or (ii) Pharmacist-led intervention comprising of computer-generated feedback, educational outreach and dedicated support. PRIMARY OUTCOME MEASURES: The proportion of patients in each practice at six and 12 months post intervention: - with a computer-recorded history of peptic ulcer being prescribed non-selective non-steroidal anti-inflammatory drugs; - with a computer-recorded diagnosis of asthma being prescribed beta-blockers; - aged 75 years and older receiving long-term prescriptions for angiotensin converting enzyme inhibitors or loop diuretics without a recorded assessment of renal function and electrolytes in the preceding 15 months. SECONDARY OUTCOME MEASURES; These relate to a number of other examples of potentially hazardous prescribing and medicines management. ECONOMIC ANALYSIS: An economic evaluation will be done of the cost per error avoided, from the perspective of the UK National Health Service (NHS), comparing the pharmacist-led intervention with simple feedback. QUALITATIVE ANALYSIS: A qualitative study will be conducted to explore the views and experiences of health care professionals and NHS managers concerning the interventions, and investigate possible reasons why the interventions prove effective, or conversely prove ineffective. SAMPLE SIZE: 34 practices in each of the two treatment arms would provide at least 80% power (two-tailed alpha of 0.05) to demonstrate a 50% reduction in error rates for each of the three primary outcome measures in the pharmacist-led intervention arm compared with a 11% reduction in the simple feedback arm. DISCUSSION: At the time of submission of this article, 72 general practices have been recruited (36 in each arm of the trial) and the interventions have been delivered. Analysis has not yet been undertaken.